Using doxycycline to protect heart muscle after heart attacks
Matrix Metalloproteinase Inhibition With Doxycycline to Prevent Adverse Remodeling After Acute Myocardial Infarction: A Pilot Study
This study is testing if the antibiotic doxycycline can help protect the heart muscle after a heart attack by seeing if it improves heart function and reduces damage.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 170 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Alberta Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Edmonton, Alberta) |
| Trial ID | NCT03508232 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of doxycycline, an antibiotic that also inhibits matrix metalloproteinase-2 (MMP-2), to prevent heart injury following acute ST-elevation myocardial infarction (STEMI). Participants will receive either doxycycline or a placebo for one week after their heart attack. The study aims to assess the impact of doxycycline on cardiac function and infarct size, building on previous findings that suggested potential benefits in heart recovery. The trial is conducted at the Royal Alexandra Hospital in Edmonton, Alberta.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who have been diagnosed with acute ST-elevation myocardial infarction and have symptom onset within 12 hours.
Not a fit: Patients with low-risk inferior STEMI, cardiogenic shock, or those with prior history of myocardial infarction or heart failure may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve heart recovery and reduce the risk of heart failure in patients after a heart attack.
How similar studies have performed: Previous studies have shown promising results for doxycycline in improving cardiac function after heart attacks, indicating that this approach has potential based on earlier findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18+ year old 2. Diagnosis of acute ST-elevation myocardial infarction (STEMI) 3. Primary STEMI 4. Symptom onset of less than 12 hours 5. Admitted to the Royal Alexandra Hospital in Edmonton, Alberta Exclusion Criteria: 1. Low risk inferior STEMI (total ST elevation plus depression \<4mm) 2. Cardiogenic shock 3. Use of thrombolytics 4. Prior history of myocardial infarction or heart failure 5. Known hypersensitivity to tetracyclines 6. Any concurrent medical condition expected to reduce life expectancy to \<1 year 7. Symptom onset to treatment (loading dose) time longer than 24 hours 8. Poor renal function (eGFR\<30 mL/min/1.73m2) or other contraindications to MRI (claustrophobia, pregnancy, PPM/ICD, sub-arachnoid clips, retained ocular foreign body)
Where this trial is running
Edmonton, Alberta
- Royal Alexandra Hospital — Edmonton, Alberta, Canada (Recruiting)
Study contacts
- Principal investigator: Richard Coulden, MD — Dept. of Radiology and Diagnostic Imaging, University of Alberta
- Study coordinator: Robert Welsh, MD
- Email: Robert.Welsh@albertahealthservices.ca
- Phone: (780) 407-3613
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.